Power Law company profile

Mirati Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2013 · IPO 2013 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$3.19B

Market cap · 2026

Revenue

$38M

Latest reported FY

Global footprint

Where Mirati Therapeutics has talent and traffic

Web traffic by country

990 monthly visits
across markets

🇺🇸 United States222.2%

🏳️ Russian Federation50.5%

🏳️ Morocco0%

Top 3 markets shown

Patent intelligence

$138M patent portfolio · 122 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$138M

4.3% of market cap · 1.6× smaller than top peer Arvinas ($223M)

122 active patent families

Where Mirati Therapeutics innovates Molecular biologyCancer researchHistone deacetylaseDiseaseBiochemistry

Below peer median on Market

Quality vs same-sector peers

Mirati Therapeutics on the five Patsnap quality dimensions

Mirati Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Mirati Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Mirati Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Mirati Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo